OVATION SCIENCE INC - OVATF STOCK NEWS

Ovation Science Inc. signs an exclusive licensing agreement with Ripco Processing Inc. for its cannabis products in Canada. Ripco will handle regulatory, manufacturing, marketing, and distribution activities, with Ovation receiving royalties. The agreement allows Ovation to launch its InVibeMD product line in early Q3 of 2024, expanding its market presence and revenue potential.

Ovation Science USA Inc. has signed an exclusive licensing agreement with MidWest Roots, LLC for its topical/transdermal cannabis formulations in Missouri. MidWest will handle regulatory, manufacturing, marketing, sales, and distribution activities, while Ovation will receive royalty income. Missouri is one of the largest cannabis markets, with over 200 dispensaries and $1.3 billion in sales as of August 2023. MidWest, known for its expertise in cannabis and consumer goods, plans to launch Ovation's products in late Q4 2023.

Ovation Science signs license agreement with Planet 13 for its topical/transdermal cannabis products for Nevada

Ovation Science Inc. has announced a new Supply and Distribution Agreement with Golfer's CBD Ltd. for its CBD topical products in the USA, UK, and Europe. This partnership aims to penetrate the lucrative golf market, which includes approximately 66.6 million golfers worldwide. By leveraging Golfer's CBD's established e-commerce and retail distribution channels, Ovation expects to generate immediate monthly revenues. Their patented skin delivery technology, Invisicare, allows for superior absorption of cannabinoids, giving Ovation a competitive edge. The initial launch in the USA is scheduled for April 2023.

Ovation Science Inc. (CSE: OVAT, OTCQB: OVATF) will exhibit at the MJ Unpacked conference from September 28-30, 2022, in Las Vegas. The company aims to meet potential licensees to promote its award-winning transdermal formulations and highlight licensing opportunities for its patented skin delivery technology, Invisicare^®. With new patent protection until 2041 and expansion in states like Oklahoma and Missouri, Ovation anticipates significant interest in its products. CEO Terry Howlett emphasized the company's focus on effective cannabinoid delivery and the unique advantages of their formulations.

Ovation Science Inc. has been awarded a patent for its transdermal creams formulated with CBD and THC, valid until February 2041. This patent strengthens the company's market position by protecting its proprietary drug delivery system, Invisicare. It covers the composition and method for delivering CBD and THC through the skin. Ovation has also expanded its licensing to four additional U.S. states, increasing its market reach to over 2,800 dispensaries. The company’s innovative approach has resulted in products showing significantly better absorption rates compared to competitors.

Ovation Science Inc. has announced an exclusive licensing agreement with Stash House Distribution to expand its cannabis formulations into Oklahoma, Missouri, New Mexico, and Mississippi. This agreement aims to increase the company's market presence from 92 dispensaries in Nevada to over 2,800 dispensaries across five states. Ovation's products utilize the patented Invisicare® technology for enhanced cannabinoid delivery, promising a significant increase in revenue through royalties based on wholesale sales. The launch is expected to occur in Q4 of 2022.

Ovation Science Inc. has launched new high-dose CBD formulations in response to the growing CBD market. The company developed a transdermal cream with 1500mg of CBD per ounce and a beauty line offering 200mg per ounce for anti-aging creams and 2000mg for body lotion. The demand for high-dose CBD topicals is increasing, supported by a projected CAGR of 21.2% for CBD products from 2021 to 2028. Ovation aims to expand its market presence beyond Nevada, where its products rank among the top five in sales at dispensaries.